These offers follow the recent agreement with the US Administration to expand access to medicines for patients living with obesity and other chronic conditions like diabetes, while lowering prices in the direct-to-patient, self-pay channel in 2026 and today, Novo Nordisk is bringing these prices to consumers months in advance of that commitment
Key Secondary Outcomes Among the nave cohorts, most secondary outcomes were in favor of tirzepatide (Table 3)
Hassan N, Rashad M, Elleithy E, Sabry Z, Ali G, Elmosalamy S
But do not expect these results to come right away, rather think of it as something that comes after a few weeks of consistent use
Comments on My Body First and foremost, I told the people closest to me (friends, family, coworkers) that I had started this medication for my health
The WBCIL Answer: Safety is paramount at WBCIL